Insulet Corporation, a company specializing in the production of tubeless insulin pumps, has announced exciting news about the launch of its revolutionary OmniPod 5 system in five more European countries.
This innovation is now available to users in Spain, Italy, the Netherlands, Belgium, and Luxembourg.
OmniPod 5 is expected in Croatia in late 2025. In the first quarter of 2025, Libre 2 Plus, which is compatible with the OmniPod 5 system, will be available in Croatia. Dexcom G7 is also anticipated as its global compatibility with OmniPod 5 expands.
OmniPod 5 Tubeless Insulin Pump and Dexcom G7 Sensor
This system integrates closed-loop technology with Dexcom G6, G7, or FreeStyle Libre 2 Plus sensors, enabling real-time automatic insulin delivery adjustments.
Automation helps maintain glucose levels within the target range, improving the quality of life for insulin-dependent diabetics.
Key Features of the OmniPod 5 System
- Automated insulin delivery – The system uses data from Dexcom or Libre CGM sensors to continuously adjust insulin doses, reducing the risk of hypoglycemia and hyperglycemia.
- Discreet and waterproof design – OmniPod 5 does not require infusion sets, offering users more freedom and comfort.
- Mobile app – Users can manage the system and view glucose and insulin data directly from their smartphones.
- Flexibility – OmniPod 5 is suitable for adults and children as young as 2 years old.
User Reactions
Users who have already tried OmniPod 5 have highlighted numerous advantages, including improved glucose control, reduced stress related to diabetes management, and increased flexibility in daily life.
Parents of children with diabetes, in particular, have emphasized how much this system eases the burden of diabetes care for their children.
Conclusion
OmniPod 5 is a game-changer in diabetes management, combining advanced technology with convenience.
With its expansion into Spain, Italy, the Netherlands, Belgium, and Luxembourg, OmniPod 5 is steadily making its way toward Croatia.
Source: adapted from investors.insulet.com
